	US 11,945,874 B2
	Anti-human CD52 immunoglobulins
Bruce L. Roberts, Southborough, MA (US); Srinivas Shankara, Shrewsbury, MA (US); William Harold Brondyk, Mansfield, MA (US); and William M. Siders, Franklin, MA (US)
Assigned to Genzyme Corporation, Cambridge, MA (US)
Filed by Genzyme Corporation, Cambridge, MA (US)
Filed on Mar. 3, 2021, as Appl. No. 17/191,440.
Application 17/191,440 is a continuation of application No. 16/380,389, filed on Apr. 10, 2019, abandoned.
Application 16/380,389 is a continuation of application No. 14/864,736, filed on Sep. 24, 2015, abandoned.
Application 14/864,736 is a continuation of application No. 14/091,083, filed on Nov. 26, 2013, abandoned.
Application 14/091,083 is a continuation of application No. 13/320,019, granted, now 8,617,554, issued on Dec. 31, 2013, previously published as PCT/US2010/034704, filed on May 13, 2010.
Claims priority of provisional application 61/177,837, filed on May 13, 2009.
Prior Publication US 2022/0010024 A1, Jan. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2893 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/64 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01)]

17 Claims

1. A method for treating a cancer in a human patient in need thereof, comprising administering to the patient an effective amount of a monoclonal anti-human CD52 antibody or an antigen-binding portion thereof, wherein the light chain and heavy chain of said antibody comprise the three complementarity determining regions (CDRs) found in

a) SEQ ID NOs: 3 and 16, respectively;

b) SEQ ID NOs: 4 and 17, respectively;

c) SEQ ID NOs: 5 and 18, respectively;

d) SEQ ID NOs: 6 and 19, respectively;

e) SEQ ID NOs: 7 and 20, respectively;

f) SEQ ID NOs: 8 and 21, respectively;

g) SEQ ID NOs: 9 and 22, respectively;

h) SEQ ID NOs: 10 and 23, respectively;

i) SEQ ID NOs: 11 and 24, respectively;

j) SEQ ID NOs: 12 and 25, respectively;

k) SEQ ID NOs: 12 and 137, respectively; or

l) SEQ ID NOs: 13 and 26, respectively.